novo nordisk fda semaglutide Novo's Ozempic wins nod to curb kidney disease risks Novo Nordisk expands patient access
Description
Purpose of Review There has been a rise in popularity and use of GLP-1 receptor agonists since their approval for obesity management
PlexusDx patients combine medication with evidence-based nutrition to maximize results and minimize side effects
Learn more about Dr
Get the support and guidance you need for lasting success
A large trial showed that semaglutide, sold as Ozempic for diabetes and as Wegovy for obesity, was better than any current medications in alleviating symptoms.
